A
fter several years in which drug makers have been pressured to release clinical trial data, a new analysis finds many companies are still doing an incomplete or inconsistent job of being transparent.
Overall, 95 percent of the 42 companies reviewed – including the 25 largest drug makers, based on sales – had a publicly accessible policy. Otherwise, however, the specifics often varied wildly in terms of what is disclosed and even how to interpret some of the policies.
Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
